Results 141 to 150 of about 8,127 (167)

Combined CDK4/6 Inhibition and Radiation: Effects on Cellular Senescence, Cell Cycle Regulation, and Cell Death in Mammary Carcinoma Cells. [PDF]

Cells
Quarz L, Distel LV, Corradini S, Hildebrand LS.   +3 more
europepmc   +1 more source

CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer. [PDF]

Cureus
Alcantar JM, Chuang FL, Kim DD.
europepmc   +1 more source

Efficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2- Breast Cancer: An Updated Meta-Analysis of Phase III Trials. [PDF]

Cancers (Basel)
Dhanoa RK, Thapa S, Kancharla P, Kurian S.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ribociclib

Reactions Weekly
  +20 more sources

Ribociclib-induced hepatotoxicity [PDF]

Journal of Oncology Pharmacy Practice, 2023
Introduction Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown a different adverse effect. In this case, persistent grade 3 hepatoxicity was observed after ribociclib.
Muhammed Muhiddin Er, Murat Araz, Mehmet Artac   +2 more
exaly   +2 more sources

Ribociclib-induced liver injury: a case report [PDF]

Frontiers in Oncology, 2023
BackgroundIdiosyncratic drug-induced liver injury (DILI) is a rare, unpredictable hepatic adverse event and the most common cause of acute liver failure in Europe and the US.
Matthias Matter, Luigi Maria Terracciano   +1 more
exaly   +2 more sources

Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment

Journal of Clinical Pharmacology, 2021
Ribociclib is an orally bioavailable, highly selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6. It is currently approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer ...
Tanay S Samant
exaly   +2 more sources

P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability [PDF]

Molecular Pharmaceutics, 2019
Ribociclib is a CDK4/6 inhibitor recently approved for the treatment of some types of breast cancer in combination with an aromatase inhibitor. It is currently investigated in the clinic to treat other malignancies, including brain tumors. Using in vitro
Stephanie Van Hoppe, Alfred Schinkel, Alejandra Martinez-Chavez   +2 more
exaly   +4 more sources

Ribociclib

Reactions Weekly, 2023
  +10 more sources

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study [PDF]

Breast, 2016
ObjectivesCyclin D–cyclin-dependent kinase (CDK) 4/6–inhibitor of CDK4/6–retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC). This study assessed the biological activity of ribociclib (LEE011;
Giuseppe Curigliano, M P Lolkema, P Gomez Pardo   +2 more
exaly   +2 more sources